American Chamber of Commerce Ireland releases annual report

Ireland now accounts for nearly 20% of all new U.S. investment flows to Europe, according to figures contained within the report. This compares favourably against France (3%) and Germany (2%) and Ireland’s share of the total U.S. investment stock in Europe has soared to 11% over the past decade and increased from 6% ten years ago.

To download the full report, please click HERE.

Read More

icon-logo_0ICON has announced its financial results for the 4th quarter and full-year 2015, and we have also given guidance for 2016. Please find details below. Full consolidated income statements and summary balance sheet data can be read here.

Some highlights from 2015 include:

– The creation of a new global innovation hub in Ireland, creating 200 scientific, IT and business jobs

– Acquisition of MediMedia Pharma Solutions,which brought new scientific communications capabilities to ICON

– The development of a new eConsent solutionand a Patient Portal by ICON’s Firecrest team in Limerick, which enable greater patient engagement in clinical trials

– A partnership with IBM that is set to revolutionise patient recruitment in clinical trials

– The acquisition of PMG Research Inc., a network of 28 clinical research centres in the US
ICON currently, operates from 90 locations in 37 countries and has approximately 11,900 employees.

ICON selected by Genomics England to support the largest genome sequencing project of its kind for cancer and rare diseases

ICON selected as Data Management Partner for the 100,000 Genomes Project

Dublin, Ireland, 9th February, 2016 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Genomics England as data management partner for the 100,000 Genomes Project.

A ground-breaking project announced by the British Prime Minister David Cameron in 2012, the100,000 Genomes Project is sequencing 100,000 whole genomes from 70,000 National Health Service (NHS) cancer and rare disease patients and their families. It aims to demonstrate a new genomic medicine service for the NHS to support better diagnosis and more personalised treatments for patients. De-identified data from the 100,000 Genomes Project will also be made available to approved researchers from industry to help accelerate the development of new treatments and diagnostic tests that are targeted at the genetic characteristics of individual patients.

Read More

ICON Releases Flex Advantage to Enhance Patient Randomisation and Clinical Supply Management in Clinical Trials

Dublin, Ireland, 19th January, 2015 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced Flex Advantage, a next-generation Interactive Response Technology (IRT) platform that offers enhanced randomisation and clinical supply management capabilities and supports the execution of adaptive trials.

To read more, please click HERE.